Corcept Therapeutics Inc. (CORT) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	$0.06	$0.36	+500.0%	—	$256.1M	—
Q1 26	-$0.14	-$0.3	-114.3%	—	$164.9M	—
Q4 25	$0.33	$0.2	-39.4%	—	$202.1M	—
Q3 25	$0.14	$0.16	+14.3%	—	$207.6M	—
Q2 25	$0.19	$0.29	+52.6%	—	$194.4M	—
Q1 25	$0.14	$0.17	+21.4%	—	$157.2M	—
Q4 24	$0.42	$0.26	-38.1%	—	$181.9M	—
Q3 24	$0.29	$0.41	+41.4%	—	$182.5M	—
Q2 24	$0.24	$0.32	+33.3%	—	$163.8M	—
Q1 24	$0.22	$0.25	+13.6%	—	$146.8M	—
Q4 23	$0.27	$0.28	+3.7%	—	$135.4M	—
Q3 23	$0.22	$0.28	+27.3%	—	$123.6M	—
Q2 23	$0.15	$0.25	+66.7%	—	$117.7M	—
Q1 23	$0.19	$0.14	-26.3%	—	$105.7M	—
Q4 22	$0.23	$0.14	-39.1%	—	$103.1M	—
Q3 22	$0.23	$0.3	+30.4%	—	$101.7M	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$0.95	—	—	$761.4M	—
FY24	—	$1.35	—	—	$675M	—
FY23	—	$1.02	—	—	$482.4M	—
FY22	—	$0.95	—	—	$401.9M

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$81.3M	$159.2M	$251.2M	$306.5M	$353.9M	$366M	$401.9M	$482.4M	$675M	$761.4M
YoY change	+61.7%	+95.8%	+57.8%	+22%	+15.5%	+3.42%	+9.8%	+20%	+39.9%	+12.8%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	81.3M	159.2M	251.2M	306.5M	353.9M	366M	401.9M	482.4M	675M	761.4M
Cost of revenue	2.1M	3.6M	5.2M	5.5M	5.6M	5.3M	5.4M	6.5M	10.9M	13M
Gross profit	79.3M	155.6M	246M	301M	348.3M	360.7M	396.5M	475.9M	664.2M	748.4M
Gross margin	97.5%	97.8%	97.9%	98.2%	98.4%	98.6%	98.7%	98.7%	98.4%	98.3%
Research & development	23.8M	40.4M	75.2M	89M	114.8M	113.9M	131M	184.4M	246.9M	254.9M
Selling, general & administrative	45.2M	62.4M	81.3M	100.4M	105.3M	122.4M	152.8M	184.3M	280.3M	448.7M
Operating expenses	69.1M	102.8M	156.5M	189.4M	220.1M	236.2M	283.8M	368.6M	527.2M	703.6M
Operating income	10.2M	52.9M	89.5M	111.6M	128.2M	124.5M	112.6M	107.3M	137M	44.8M
Operating margin	12.5%	33.2%	35.6%	36.4%	36.2%	34%	28%	22.2%	20.3%	5.88%
Non-operating income, net	—	—	—	—	—	—	—	—	—	—
Pretax income	8.1M	52.8M	92.2M	116.7M	131.6M	125M	116.2M	124.6M	161.5M	66.5M
Income tax	0	-76.3M	16.7M	22.5M	25.6M	12.5M	14.8M	18.4M	20.3M	-33.2M
Net income	8.1M	129.1M	75.4M	94.2M	106M	112.5M	101.4M	106.1M	141.2M	99.7M
Net margin	10%	81.1%	30%	30.7%	30%	30.7%	25.2%	22%	20.9%	13.1%
EBITDA	10.3M	53M	89.7M	113.8M	130.4M	128M	116.1M	109.6M	138.3M	46.7M
EPS	0.07	1.14	0.65	0.82	0.92	0.97	0.95	1.02	1.35	0.95
Diluted EPS	0.07	1.04	0.6	0.77	0.85	0.89	0.87	0.94	1.23	0.82

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	123.6M	135.4M	146.8M	163.8M	182.5M	181.9M	157.2M	194.4M	207.6M	202.1M	164.9M	256.1M
Cost of revenue	1.6M	1.9M	2.5M	2.5M	2.9M	3M	2.4M	3.4M	4.6M	2.5M	2.9M	4.1M
Gross profit	122M	133.5M	144.3M	161.3M	179.7M	178.9M	154.8M	191M	203M	199.6M	162M	252.1M
Gross margin	98.7%	98.6%	98.3%	98.5%	98.4%	98.4%	98.5%	98.2%	97.8%	98.7%	98.3%	98.4%
Research & development	45.5M	54.7M	58.5M	58.7M	59.3M	70.3M	60.7M	60.5M	68.8M	64.9M	66.3M	53.9M
Selling, general & administrative	45.3M	47.2M	56.3M	66.9M	73.7M	83.4M	90.7M	103.9M	124M	130.2M	145.4M	156.9M
Operating expenses	90.8M	101.9M	114.8M	125.7M	133.1M	153.7M	151.4M	164.3M	192.8M	195.1M	211.6M	210.8M
Operating income	31.2M	31.7M	29.5M	35.6M	46.6M	25.3M	3.4M	26.7M	10.2M	4.5M	-49.6M	41.3M
Operating margin	25.2%	23.4%	20.1%	21.7%	25.5%	13.9%	2.17%	13.7%	4.92%	2.22%	-30.1%	16.1%
Non-operating income, net	—	—	—	—	—	—	—	—	—	—	—	—
Pretax income	36.4M	36.8M	35M	41.6M	52.9M	32M	9.6M	31.7M	15.2M	9.9M	-44.7M	45.9M
Income tax	5M	5.5M	7.2M	6.1M	5.7M	1.2M	-10.9M	-3.5M	-4.4M	-14.4M	-13M	2.9M
Net income	31.4M	31.4M	27.8M	35.5M	47.2M	30.7M	20.5M	35.1M	19.7M	24.3M	-31.8M	43M
Net margin	25.4%	23.2%	18.9%	21.7%	25.9%	16.9%	13.1%	18.1%	9.47%	12%	-19.3%	16.8%
EBITDA	31.5M	32.3M	29.7M	35.8M	47.1M	25.7M	3.9M	27.1M	10.7M	5M	-49M	42.2M
EPS	0.31	—	0.27	0.34	0.45	0.29	0.19	0.33	0.19	0.23	-0.3	0.4
Diluted EPS	0.28	—	0.25	0.32	0.41	0.26	0.17	0.29	0.16	0.2	-0.3	0.36

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	802.7M	2.1B	1.5B	1.4B	3B	2.3B	2.2B	3.4B	5.2B	3.6B	12.5B
Enterprise value	765.8M	2B	1.3B	1.1B	2.6B	2.1B	1.7B	3B	4.8B	3.2B	12.3B
Shares outstanding	110.6M	113.5M	115.3M	114.3M	115.4M	115.7M	106.8M	103.6M	103.2M	103.9M	103.9M

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	98.6	15.9	20.4	14.7	28.5	20.4	21.4	31.7	36.8	36.3	258
P/S	9.87	12.9	6.13	4.51	8.53	6.26	5.4	6.97	7.71	4.75	15.1
P/B	19.4	10.7	5.59	3.73	5.77	6.09	4.32	6.64	7.65	5.58	17.8
EV/EBITDA	74.6	37	14.9	9.77	19.8	16.2	15	27.3	34.9	69.6	1.5K
EV/Sales	9.42	12.3	5.31	3.63	7.29	5.65	4.33	6.21	7.15	4.27	14.7
Earnings yield	1.01%	6.3%	4.89%	6.81%	3.51%	4.91%	4.68%	3.16%	2.71%	2.76%	0.39%
FCF yield	2.27%	2.95%	7.49%	9.76%	4.99%	7.31%	5.53%	3.77%	3.77%	3.92%	0.62%
PEG	—	—	—	—	—	—	—	—	—	—	12.2

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	97.5%	97.8%	97.9%	98.2%	98.4%	98.6%	98.7%	98.7%	98.4%	98.3%	98.4%
Operating margin	12.5%	33.2%	35.6%	36.4%	36.2%	34%	28%	22.2%	20.3%	5.88%	16.1%
Net margin	10%	81.1%	30%	30.7%	30%	30.7%	25.2%	22%	20.9%	13.1%	6.64%
ROE	19.7%	67.6%	27.3%	25.4%	20.3%	29.9%	20.2%	20.9%	20.8%	15.4%	8.23%
ROA	11.8%	58.5%	24.2%	22.8%	18.5%	26.6%	17.4%	17.1%	16.8%	11.9%	0.47%
ROIC	225.8%	51.7%	106%	91.3%	121.2%	73.3%	137.9%	65.9%	39.5%	15.9%	1.57%
Return on tangible assets	11.8%	58.5%	24.2%	22.8%	18.5%	26.6%	17.4%	17.1%	16.8%	11.9%	6.21%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	2.4	4.2	6.66	7.91	10.1	5.6	6.89	4.39	3.35	2.92	2.86
Quick ratio	2.31	4.05	6.52	7.77	9.97	5.5	6.8	4.31	3.26	2.85	2.77
Debt / equity	0.35	—	0	0.01	0	0	0	0	0.01	0.01	0.01
Debt / assets	0.21	—	0	0.01	0	0	0	0	0.01	0.01	0.01
Net debt / EBITDA	-3.59	—	-2.3	-2.4	-3.36	-1.74	-3.71	-3.36	-2.72	-7.84	-33.9
Interest coverage	4.99	1.1K	—	—	—	—	—	—	—	—	—
Effective tax rate	0%	0%	18.2%	19.3%	19.4%	9.99%	12.7%	14.8%	12.6%	0%	0%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	0.74	1.4	2.18	2.68	3.07	3.16	3.76	4.66	6.54	7.33	7.97
EPS (basic)	0.07	1.14	0.65	0.82	0.92	0.97	0.95	1.02	1.35	0.95	0.95
EPS (diluted)	0.07	1.04	0.6	0.77	0.85	0.89	0.87	0.94	1.23	0.82	0.45
Book value per share	0.37	1.68	2.39	3.25	4.53	3.25	4.7	4.89	6.58	6.24	6.54
FCF per share	0.16	0.53	1	1.18	1.31	1.45	1.12	1.23	1.9	1.37	0.9
Cash per share	0.47	0.78	1.79	2.41	3.82	1.93	4.04	3.56	3.71	3.58	2.85
Capex per share	0	0	0	0.01	0.01	0	0	0	0.02	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	0.24%	0.26%	0.12%	0.35%	0.35%	0.13%	0.1%	0.03%	0.32%	—	—
Capex / operating cash flow	1.41%	0.81%	0.26%	0.85%	0.85%	0.29%	0.42%	0.11%	1.33%	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—	0%

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$123.6M	$135.4M	$146.8M	$163.8M	$182.5M	$181.9M	$157.2M	$194.4M	$207.6M	$202.1M	$164.9M	$256.1M
YoY change	+21.5%	+31.4%	+39%	+39.1%	+47.7%	+34.3%	+7.09%	+18.7%	+13.7%	+11.1%	+4.89%	+31.7%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	51.5M	88.7M	206.8M	276M	440.7M	223.5M	431.7M	368.2M	383.3M	372.2M
Receivables	9.9M	15.3M	17.6M	19.9M	26.2M	27.6M	31.1M	41.1M	54M	59.8M
Inventory	2.3M	4.6M	4.7M	5.4M	4.9M	5M	6.1M	7.7M	12.4M	12.9M
Total current assets	65.7M	124.2M	236.8M	307.4M	478.5M	266.5M	499.3M	458.6M	471.6M	485.5M
Property, plant & equipment	205K	518K	655K	4.5M	4.2M	1.5M	2.4M	315K	8M	6.5M
Goodwill & intangibles	—	—	—	—	—	—	—	—	—	—
Total assets	68.8M	220.5M	311.7M	412.3M	571.7M	423.8M	583.4M	621.5M	840.6M	836.7M
Accounts payable	2.3M	8.6M	8.3M	7.5M	10.6M	6.9M	12M	17.4M	15.4M	40.4M
Short-term debt	14.7M	—	—	1.6M	2M	526K	1.1M	151K	829K	1.1M
Total current liabilities	27.4M	29.6M	35.6M	38.8M	47.5M	47.5M	72.5M	104.5M	140.8M	166.1M
Long-term debt	—	—	0	1.9M	501K	0	—	—	6.1M	5M
Total liabilities	27.4M	29.6M	35.8M	41.1M	48.4M	48M	81.6M	114.8M	161M	188.8M
Shareholders' equity	41.4M	191M	275.9M	371.2M	523.3M	375.8M	501.8M	506.7M	679.6M	647.8M
Total debt	14.7M	—	0	3.5M	2.6M	526K	1.1M	151K	6.9M	6.1M
Net debt	-36.9M	—	-41.6M	-27.8M	-73.6M	-77.1M	-65.2M	-135.4M	-120.7M	-114.4M

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	355.2M	368.2M	410.8M	473.2M	380.3M	383.3M	322.8M	342.2M	421.7M	372.2M	338.2M	308.2M
Receivables	34.6M	41.1M	61.5M	53.8M	59.7M	54M	61.8M	64.6M	69.6M	59.8M	39.1M	76.9M
Inventory	7.5M	7.7M	7.2M	8.3M	8.1M	12.4M	14.4M	12.3M	12.3M	12.9M	12.9M	13.2M
Total current assets	431.5M	458.6M	503.4M	560.8M	467M	471.6M	438.5M	443.1M	541.1M	485.5M	426M	439.7M
Property, plant & equipment	480K	315K	188K	7.2M	8.4M	8M	7.7M	7.3M	6.9M	6.5M	10.4M	12M
Goodwill & intangibles	—	—	—	—	—	—	—	—	—	—	—	—
Total assets	594M	621.5M	655.9M	714.6M	784.3M	840.6M	846.5M	801.7M	823.6M	836.7M	814.9M	888.7M
Accounts payable	16.7M	17.4M	12.6M	19.5M	18.6M	15.4M	27.9M	23.5M	34.4M	40.4M	33.3M	14.9M
Short-term debt	225K	151K	76K	44K	432K	829K	984K	1M	1.1M	1.1M	1.6M	1.9M
Total current liabilities	121.9M	104.5M	97.2M	100.8M	126.2M	140.8M	143.1M	144.7M	172.3M	166.1M	149.2M	153.8M
Long-term debt	—	—	—	5.6M	6.4M	6.1M	5.9M	5.6M	5.3M	5M	8M	7.5M
Total liabilities	132.3M	114.8M	108.1M	118.3M	145.4M	161M	163.2M	165.9M	191.7M	188.8M	176.9M	182.9M
Shareholders' equity	461.7M	506.7M	547.9M	596.2M	638.8M	679.6M	683.3M	635.8M	631.9M	647.8M	638M	705.8M
Total debt	225K	151K	76K	5.7M	6.8M	6.9M	6.8M	6.6M	6.4M	6.1M	9.6M	9.4M
Net debt	-111.6M	-135.4M	-149.7M	-122.9M	-130.5M	-120.7M	-83M	-96.1M	-118.8M	-114.4M	-99.1M	-101.6M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	8.1M	129.1M	75.4M	94.2M	106M	112.5M	101.4M	106.1M	141.2M	99.7M
Depreciation & amortization	87K	106K	236K	2.2M	2.2M	3.5M	3.4M	2.4M	1.3M	1.9M
Stock-based compensation	7.1M	13.4M	23.7M	29.3M	33.5M	42.9M	42.4M	48.9M	61.4M	84.5M
Change in working capital	-3.5M	-14.4M	2.7M	-12.4M	-11.4M	-1.7M	-15.7M	-5.8M	-682K	12.4M
Operating cash flow	13.7M	52M	114.4M	128.4M	145.9M	161.6M	99.1M	122.2M	163M	142M
Capital expenditure	-194K	-419K	-298K	-1.1M	-1.2M	-469K	-413K	-139K	-2.2M	—
Investing cash flow	-194K	-73.5M	-90.8M	-117.8M	-119.3M	136.1M	-114.3M	90.9M	-177.6M	70M
Dividends paid	—	—	—	—	—	—	—	—	—	—
Share repurchases	0	0	-23.7M	-31M	-9.9M	-296M	0	-145.4M	0	0
Financing cash flow	-29.6M	-30.3M	-23.7M	-37.1M	-11M	-318.8M	-21.7M	-154.5M	-22.3M	-72.9M
Net change in cash	-16M	-51.7M	-6K	-26.5M	15.6M	-21.1M	-36.9M	58.5M	-36.9M	139M
Free cash flow	18.2M	60.5M	115.4M	135M	150.7M	167.4M	119.9M	126.9M	195.9M	141.8M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	31.4M	31.4M	27.8M	35.5M	47.2M	30.7M	20.5M	35.1M	19.7M	24.3M	-31.8M	43M
Depreciation & amortization	289K	630K	179K	198K	499K	460K	462K	469K	477K	482K	598K	863K
Stock-based compensation	12.9M	13.1M	13.2M	15.2M	16.1M	16.8M	21.8M	19M	22.9M	20.8M	23M	29.4M
Change in working capital	5.9M	-5.2M	-10.2M	12M	-4.8M	2.3M	5.6M	-13.7M	1.9M	19M	9.8M	-60.4M
Operating cash flow	38.8M	36.1M	23.8M	48.9M	43.8M	46.5M	34.7M	23.2M	54.5M	38.4M	-16.8M	33.5M
Capital expenditure	-37K	0	—	-416K	-1.6M	-121K	-104K	-57K	—	—	—	—
Investing cash flow	-109.6M	17.1M	-9M	-60.2M	-44M	-64.4M	-3.2M	70.1M	14.6M	-11.8M	4.7M	-26.7M
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	0	0	—	—	0	0	—	—	—	—	—	—
Financing cash flow	-5.1M	-995K	-1.8M	-1.9M	-11.7M	-7M	-15.8M	-12.4M	-8.2M	-36.5M	-5.8M	-11.5M
Net change in cash	-75.8M	52.2M	13.1M	-13.2M	-11.9M	-24.9M	15.7M	80.9M	61M	-9.9M	-17.8M	-4.6M
Free cash flow	52.9M	5.9M	23.8M	40.8M	72.2M	59.2M	5M	44.2M	54.5M	38.4M	-17M	31M

Corcept Therapeutics Inc. Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement